ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Rituximab"

  • Abstract Number: 2633 • 2019 ACR/ARP Annual Meeting

    Efficacy of Remission Induction Regimens in Elderly Patients with ANCA-Associated Glomerulonephritis

    Audrey Hopkins1, Stanley Chu 2, Philip Seo 3, Eric Gapud 1, Brendan Antiochos 1, Shaker Eid 1, Jason Liebowitz 1 and Duvuru Geetha 1, 1Johns Hopkins Bayview Medical Center, Baltimore, 2Johns Hopkins University, Baltimore, 3Johns Hopkins Medicine, Baltimore, MD

    Background/Purpose: Induction regimens using either cyclophosphamide (CYC) or rituximab (RTX) have been shown to have similar efficacy and similar rates of adverse events in randomized…
  • Abstract Number: 2634 • 2019 ACR/ARP Annual Meeting

    ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients

    Laura van Dam1, Ebru Dirikgil 2, Edwin Bredewold 2, Argho Ray 2, Ton Rabelink 2, Cees van Kooten 2 and Onno Teng 2, 1LUMC, Leiden, Zuid-Holland, Netherlands, 2LUMC, Leiden, Netherlands

    Background/Purpose: Recent studies have demonstrated that in patients with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) with successful remission-induction (RI) after cyclophosphamide (CYC), maintenance treatment with…
  • Abstract Number: 2902 • 2019 ACR/ARP Annual Meeting

    The Use and Safety of Rituximab in Connective Tissue Disease Associated Interstitial Lung Disease

    Christopher Mesa1, Snehaja Yadlapati 1 and Myriam Guevara 2, 1Louisiana State University Health Science Center, New Orleans, LA, 2Louisiana State University School of Medicine, New Orleans

    Background/Purpose: Interstitial Lung Disease (ILD) is the most common lung manifestation in Connective Tissue Diseases (CTD). It is present in most types of CTD, such…
  • Abstract Number: 2911 • 2019 ACR/ARP Annual Meeting

    A Randomised, Open Labelled Clinical Trial to Investigate Synovial Mechanisms Determining Response – Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis Patients Failing TNF Inhibitor Therapy

    Frances humby 1, Maya H. Buch 2, Patrick Durez 3, Myles Lewis 1, Michele Bombardieri 1, Hasan Rizvi 4, Stephen Kelly 4, Liliane Fosatti 1, Rebecca Hands 1, Giovanni Giorli 1, Arti Mahto 1, Carlomaurizio Montecucco 5, Bernard Lauwerys 6, Vasco Romao 7, Arthur Pratt 8, Serena Bugatti 9, Nora Ng 10, Felice Rivellese 1, Pauline Ho 11, Mattia Bellan 12, Mattia Congia 13, Patrick Verschueren 14, Pier Paolo Sainaghi 12, Nagui Gendi 15, Bhaskar Dasgupta 16, Alberto Cauli 17, Piero Reynolds 18, Juan Cañete 19, Robert J. Moots 20, Peter Taylor 21, Christopher Edwards 22, John Isaacs 8, Peter Sasieni 23, João Eurico Fonseca 24, Ernest Choy 25 and Costantino Pitzalis26, 1Queen Mary University of London, London, United Kingdom, 2University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, 3Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, UCL Saint-Luc, Brussels, Belgium, 4Barts Health NHS Trust, London, United Kingdom, 5Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, Pavia, Italy, 6University of Louvain, Louvain, Belgium, 7University of Lisbon, Lisbon, Portugal, 8University of Newcastle, Newcastle, United Kingdom, 9University of Pavia, Pavia, Italy, 10Guys and St Thomas NHS Trust, London, United Kingdom, 11University of Manchester, Manchester, United Kingdom, 12University of Novara, Novara, Italy, 13University of Cagliari, Cagliari, Italy, 14University of Leuven, Leuven, Belgium, 15Basildon Hospital NHS Trust, Basildon, United Kingdom, 16Southend University Hospital, NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, 17Rheumatology Unit, University Clinic AOU and University of Cagliari, Cagliari, Italy, 18Homerton University NHS Trust, London, United Kingdom, 19Rheumatology Department, Hospital Clínic and IDIBAPS,, Barcelona, Spain, 20Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, 21University of Oxford, Oxford, United Kingdom, 22University of Southampton, Southampton, United Kingdom, 23Kings College London, London, United Kingdom, 24Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa; Centro Académico de Medicina de Lisboa; Lisbon, Portugal., Lisbon, Portugal, 25Cardiff University School of Medicine, Cardiff, United Kingdom, 26Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom

    Background/Purpose: Although biologic therapies have transformed the outlook for rheumatoid arthritis (RA), the lack of a major treatment response in over 50% of patients, the…
  • Abstract Number: 309 • 2019 ACR/ARP Annual Meeting

    Increasing Capacity and Reducing Costs of Rituximab Administration

    Zachary Wallace1, Tyler Harkness 1, Kimberly Blumenthal 1, Hyon K. Choi 2, John Stone 3 and Rochelle Walensky 1, 1Massachusetts General Hospital, Boston, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: Rituximab (RTX) is associated with a large cost burden on the healthcare system and treatment delays that often exceed one month because the long…
  • Abstract Number: 383 • 2019 ACR/ARP Annual Meeting

    Retroperitoneal Fibrosis- a Single Center Experience

    Mert Oztas1, Emir Cerme 2, Izzet Altun 3 and Serdal Ugurlu 4, 1Istanbul University-Cerrahpasa,Department of Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, 3Mayo Clinic, Scottsdale, AZ, 4Istanbul University - Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, istanbul, Turkey

    Background/Purpose: Idiopathic retroperitoneal fibrosis (iRPF) is a rare, chronic, progressive disorder of unknown etiology and characterized by the presence of inflammatory and fibrous retroperitoneal tissue…
  • Abstract Number: 537 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety Results from a Randomized Double-Blind Study That Compared the Proposed Biosimilar ABP 798 with Rituximab in Subjects with Moderate to Severe RA

    Gerd Burmester1, Edit Drescher 2, Pawel Hrycaj 3, David Chien 4, Zhiying Pan 4 and Stanley Cohen 5, 1Charité—University Medicine Berlin, Berlin, Germany, 22Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary, 3Koscian Municipal Hospital, Koscian, Poland, 4Amgen, Thousand Oaks, CA, 5Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: ABP 798 is being developed as a biosimilar to rituximab, a CD20-directed cytolytic antibody that is approved in the US and EU for treatment…
  • Abstract Number: 539 • 2019 ACR/ARP Annual Meeting

    A Randomized Double-Blind Study Comparing Pharmacokinetics (PK) and Pharmacodynamics (PD) of ABP 798 with Rituximab in Subjects with Moderate to Severe RA

    Gerd Burmester1, Stanley Cohen 2, David Chien 3, Vincent Chow 3 and Zhiying Pan 3, 1Charité—University Medicine Berlin, Berlin, Germany, 2Metroplex Clinical Research Center, Dallas, TX, 3Amgen, Thousand Oaks, CA

    Background/Purpose: ABP 798 is being developed as a biosimilar to rituximab, a CD20-directed cytolytic antibody that is approved in the US and EU for treatment…
  • Abstract Number: 793 • 2019 ACR/ARP Annual Meeting

    Rituximab for Rapidly Progressive Juvenile Systemic Sclerosis: A Proof-of-concept Study in Four Patients

    Roberto Dal Pozzolo 1, Alessandra Meneghel 1, Biagio Castaldi 1, Giorgia Martini 1, Renzo Marcolongo 2 and Francesco Zulian3, 1Dept. of Woman's and Child's Health, University of Padua, Italy, Padua, Italy, 2Clinical Immunology, Dept. of Medicine, University of Padua, Padua, Italy, 3Department of Woman and Child Health, University of Padua, Italy, Padova, Italy

    Background/Purpose: Juvenile Systemic Sclerosis (JSSc) is a rare multi-systemic disease characterized by fibrous changes of the skin and internal organs [1]. Patients with “rapidly progressive”…
  • Abstract Number: 806 • 2019 ACR/ARP Annual Meeting

    A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease

    Rona Smith1, David Jayne 2 and Peter Merkel 3, 1University of Cambridge, Cambridge, England, United Kingdom, 2Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, 3University of Pennsylvania, Philadelphia

    Background/Purpose: Rituximab is an effective therapy for induction of remission in ANCA-associated vasculitis (AAV).  However, the effect of rituximab is not sustained, and relapse rates…
  • Abstract Number: 845 • 2019 ACR/ARP Annual Meeting

    Comparison of Rituximab-Associated Hypogammaglobulinemia Rates in Patients with Systemic Rheumatologic Conditions

    Stefanie Wade1 and Vasileios Kyttaris 1, 1Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

    Background/Purpose: Rituximab (RTX) is used in a wide variety of rheumatic disease. Emerging guidelines suggest measuring immunoglobulins (Ig) at pre-treatment screening and prior to repeat…
  • Abstract Number: 882 • 2019 ACR/ARP Annual Meeting

    Serum Anti-Vimentin Autoantibodies May Uniquely Predict Response to Therapy in Lupus Nephritis

    Andrew Kinloch1, Matthew Cascino 2, Jian Dai 3, Rene Bermea 1, Kichul Ko 1, Margaret Vesselits 4, Maureen Legendre 5, Michael Okoreeh 1, David Markovitz 5, Leonard Dragone 6, Michael Townsend 3 and Marcus Clark 1, 1University of Chicago, Chicago, IL, 2Genentech, Inc., San Fransisco, CA, 3Genentech, San Fransisco, CA, 4University of Chicago, Chicago, 5University of Michigan, Ann Arbor, MI, 6UCSF, San Fransisco, CA

    Background/Purpose: Tubulointerstitial inflammation (TII) in lupus nephritis (LN) is associated with a worse prognosis. Vimentin, a cytoplasmic antigen, is commonly targeted by in situ activated…
  • Abstract Number: 966 • 2019 ACR/ARP Annual Meeting

    Minimal Residual Autoimmunity After Rituximab in ANCA-associated Vasculitis Patients

    Laura van Dam1, Jelle Oskam 2, Sylvia Kamerling 2, Eline Arends 2, Edwin Bredewold 2, Magda Berkowska 2, Jacques van Dongen 2, Ton Rabelink 2, Cees van Kooten 2 and Onno Teng 2, 1LUMC, Leiden, Zuid-Holland, Netherlands, 2LUMC, Leiden, Netherlands

    Background/Purpose: Background: B-cell depletion with rituximab (RTX) is an effective treatment for ANCA-associated vasculitis (AAV) patients. Repeated RTX upon B-cell repopulation or return of ANCAs…
  • Abstract Number: 126 • 2018 ACR/ARHP Annual Meeting

    Direct Interaction between Autoreactive B Cells and Endothelial Colony Forming Cells Induces Cytokine Production from B Cells through B Cell Receptor and IL-6-JAK2-STAT3 Signaling Pathway, Suppressing Proliferation of Endothelial Colony Forming Cells in Systemic Sclerosis

    Takemichi Fukasawa1, Ayumi Yoshizaki1, Satoshi Ebata1, Kouki Nakamura1, Yoshihide Asano1, Yutaka Kazoe2, Kazuma Mawatari2, Takehiko Kitamori2 and Shinichi Sato1, 1Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Department of Applied Chemistry, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan

    Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disorder that is characterized by fibrosis and vascular damage in the skin and other visceral organs, with…
  • Abstract Number: 1561 • 2018 ACR/ARHP Annual Meeting

    B Lymphocyte Depletion Therapy with Rituximab in Primary Sjögren’s Syndrome: Indications , Effectiveness and Ultrasonographic Response

    Francesco Ferro, Nicoletta Luciano, Elena Elefante, Maurizio Mazzantini, Marta Mosca and Chiara Baldini, Rheumatology Unit, University of Pisa, Pisa, Italy

    Background/Purpose: Aim of this study was to assess indications, effectiveness, clinical and ultrasonographic response to rituximab (RTX) therapy in primary Sjögren’s syndrome (pSS), focusing in…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology